XML 41 R22.htm IDEA: XBRL DOCUMENT
v3.23.3

Research and Development Costs (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2023
Research and Development [Abstract] |
Schedule of Research and Development Costs | A summary of research and development costs for the three months and nine months ended September 30, 2023 and 2022, including costs associated with clinical trials involving the Company’s lead clinical compound LB-100, are summarized below based on the respective geographical regions where such costs have been incurred. Schedule of Research and Development Costs
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
United States |  | $ | 68,315 |  |  | $ | 161,744 |  |  | $ | 291,846 |  |  | $ | 316,565 |
Spain |  |  | 9,496 |  |  |  | 1,246 |  |  |  | 283,035 |  |  |  | 348,850 |
China |  |  | 3,108 |  |  |  | 63,330 |  |  |  | 17,198 |  |  |  | 81,050 |
Netherlands |  |  | 51,568 |  |  |  | 46,068 |  |  |  | 156,950 |  |  |  | 149,184 |
Total |  | $ | 132,487 |  |  | $ | 272,388 |  |  | $ | 749,029 |  |  | $ | 895,649 |
Research and development expense |  | $ | 132,487 |  |  | $ | 272,388 |  |  | $ | 749,029 |  |  | $ | 895,649 |

X
- Definition Tabular disclosure of research and developement. + References No definition available. + Details
Name: | LIXT_ResearchDevelopmentTableTextBlock
Namespace Prefix: | LIXT_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration